277 results on '"Brusamolino, E."'
Search Results
2. CFU-GM Growth from Peripheral Blood Stem Cells (PBSC) Before and After Cryopreservation : Comparison with Bone Marrow Cells
3. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
4. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
5. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
6. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
7. Post-transplantation cyclophosphamide is safe and effective to prevent immunological reaction after unmanipulated haploidentical bone marrow transplantation following nonmyeloablative conditioning for advanced lymphomas: 109
8. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea
9. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy
10. ASCT is not superior to conventional-dose, anthracyclin-based chemotherapy in peripheral T-cell lymphoma
11. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma
12. Erratum: Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
13. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
14. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma
15. Adenosine Deaminase and Terminal Transferase in Leukemic Cells
16. Clinical Relevance of Terminal Transferase and Adenosine Deaminase in Leukemia
17. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
18. In vivo purging followed by autotransplant induces long clinical and molecular remission in relapsed/refractory follicular lymphoma patient
19. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
20. PET/CT Response Analysis in Primary Mediastinal Diffuse Large B-Cell Lymphoma (PMBL): Preliminary Results of the IELSG-26 Study
21. PET/CT RESPONSE ANALYSIS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMBL): PRELIMINARY RESULTS OF THE IELSG-26 STUDY
22. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study
23. Rituximab combined with M/VACOP-B and radiotherapy in primary mediastinal large B-cell lymphoma (PMLBCL): A prospective italian phase II study of Intergruppo Italiano Linfomi (IIL)
24. Risk of second cancer in nongastric marginal zone B-cell lymphomas of MALT: a population-based study from Northern Italy
25. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist
26. Nongastric marginal zone B-cell lymphoma of MALT: prognostic value of disease dissemination
27. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
28. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
29. Leucemia mieloide cronica e sindromi mieloproliferative croniche
30. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
31. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity
32. EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS
33. TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY
34. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
35. The risk of acut leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration chemotherapy: a case-control study
36. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
37. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
38. 46 Significant reduction of second breast cancer risk in patients treated with involved nodes radiation therapy for early stage Hodgkin's lymphoma
39. First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions
40. Plasma cell leukemia: A report on 15 patients
41. Risk assessment in myelodysplastic syndromes: Value of clinical, hematologic and bone marrow histologic findings at presentation
42. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
43. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma
44. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
45. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups
46. Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives
47. Health cooperation in an hospital of a rural area of Ivory Coast: analysis of the priorities and of the different levels at which cooperation can take place
48. Analysis of efficacy and long-term toxicity in the treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by limited radiotherapy
49. 161 G-CSF treatment after intensive chemotherapy in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: A randomized study
50. Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.